Nab-paclitaxel trials for Pancreatic Adenocarcinoma

All Nab-paclitaxel trials · All Pancreatic Adenocarcinoma trials

Phase breakdown

Recruiting trials studying Nab-paclitaxel for Pancreatic Adenocarcinoma

• A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
  NCT05624918 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
  NCT06483555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
  NCT07621718 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations

Common questions

How many trials study Nab-paclitaxel for Pancreatic Adenocarcinoma?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.